Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Crinetics Pharmaceuticals, Inc. - Common Stock
(NQ:
CRNX
)
47.96
-0.75 (-1.54%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 26, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Crinetics Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
Next >
Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference
December 18, 2025
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)
December 11, 2025
Phase 3 study builds on positive phase 2 results showing rapid and sustained reductions in key disease biomarkers and clinical measures of CAH
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 10, 2025
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors
December 03, 2025
Initiation of trial marks milestone for Crinetics’ novel nonpeptide drug conjugate platform
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome
November 20, 2025
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 10, 2025
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
November 06, 2025
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics to Highlight Neuroendocrine Tumor Research Progress at the 2025 North American Neuroendocrine Tumor Society Annual Meeting
October 23, 2025
Preliminary analysis of one-year progression-free survival data from Phase 2 study of novel SST2 agonist paltusotine under investigation for carcinoid syndrome demonstrated potential anti-tumor...
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 10, 2025
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
October 06, 2025
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly
September 25, 2025
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 10, 2025
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH)
August 21, 2025
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 11, 2025
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
August 07, 2025
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025
July 13, 2025
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025
July 11, 2025
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Announces July 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 10, 2025
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline
June 30, 2025
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025
June 16, 2025
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 10, 2025
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025
May 23, 2025
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025
May 15, 2025
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
May 08, 2025
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025
April 11, 2025
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 10, 2025
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly
March 27, 2025
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 10, 2025
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
February 27, 2025
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer
February 24, 2025
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
